VolFlashVOLFLASH
Sign inUpgrade to Pro
Relevance 72Medium Market moves

The FDA declined to approve one of biotech’s most closely watched cancer drugs. The company’s stock tumbled.

Published2026-11-16 20:45 UTC
Updated2026-11-16 20:46 UTC
StatusAnalysed
Sourcemarketwatch Feed
CoverageSingle source
Market relevance59
Source confidence45
Freshness37
Asset link confidence—No listed assets

Metrics metrics-v2.1 · Experimental; not used for ranking · Method

RegulationPlunge
Read source ↗
01

What happened

Reported fact

The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.

The text and links above come from the source outlets. The transmission paths and judgement below are VolFlash inference based on those facts, not claims made by the outlets.

02

Why it matters

VolFlash inference

FDA rejects Summit's lung-cancer drug for lack of overall survival benefit

Failure on OS endpoint undermines biotech valuation benchmark and regulatory credibility

An analytical judgement, not a statement of fact, and not a price forecast.

03

Transmission paths

Event → variable → asset class → asset
DirectSMMT is Summit Therapeutics ticker
  1. FDA rejection of Summit drug
  2. single-asset value destruction
  3. equity
  4. SMMT

1 more paths are members-only. Unlock full analysis

04

Affected assets

No direct listed exposure identified — we do not map to an instrument when none is publicly tradable.

05

Watch next

The watchlist is members-only — knowing which indicators to track is half the value. Unlock full analysis

Next on the calendarOpen the full calendar →
06

Invalidation conditions

The invalidation conditions are members-only — knowing what would prove this wrong matters as much as the call itself. Unlock full analysis

07

Market reaction

Unavailable — no verified market reaction data.

VolFlash captures a market snapshot only within 5 minutes of a scheduled data release, with window, baseline and source attached. This event has no such capture, so there is no verified before/after price data — and we do not infer one.

08

Related events

Same topic / category
One email a day — don't miss the big ones

The 8 highest-severity events of the past 24h, with our read and source links. Unsubscribe anytime.

Published 2026-11-16 20:45:54 · Source marketwatch · Automatically aggregated and analysed — verify against the original source.

Public information plus VolFlash reasoning. Not investment advice; no price targets.

All sources freshEvents 2m agoCollectors 2m agoCalendar 29m agoAnalysis 1m agoMarket data 47s agoDark pool 5h ago